Gene expression in "young adult type" breast cancer: A retrospective analysis

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13688-13702

  Johnson, Rebecca H ^a   Hu, Pingzhao ^b   Fan, Cheng ^c   Anders, Carey K ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Gene expression; Premenopausal; Survival; Young

Indexed keywords

ANTINEOPLASTIC AGENT; CXCL2 CHEMOKINE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN MYBL2; PROTEIN SNAI1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; AGING; ANGPTL4 GENE; ARTICLE; BREAST CANCER; BUB1 GENE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; CXCL2 GENE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; KRT5 GENE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; METASTASIS; MYCN GENE; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR INVASION; AGE; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGE FACTORS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84931083862     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4051     Document Type: Article

References (36)

1. Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, Rampini A, Marrazzo L, Di Cataldo V, Bianchi S, Cataliotti L, Biti G. The impact of young age on breast cancer outcome. Eur J Surg Oncol 2010; 36:639-645.
2. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009; 36:237-249.
3. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009; 208:341-347.
4. Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011; 29:e18-20. Epub 2010 Nov 29.
5. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14:1368-1376.
6. Thomas GA, Leonard RC. How age affects the biology of breast cancer. Clin Oncol 2009; 21:81-85.
7. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008; 66:65-74.
8. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
9. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006; 66:10292-10301.
10. Johnson WE, Rabinovic A, and Li C. Adjusting batch effects in microarray expression data using Empirical Bayes methods. Biostatistics 2007; 8:118-127.
11. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-1167.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995; 85:289-300.
13. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982; 69:553-566.
14. Therneau T, Grambsch P. Modeling Survival Data:Extending the Cox Model. New York: Springer-Verlag 2000.
15. Keegan TH, Derouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012; 14:R55.
16. Azim HA Jr, Michiels S, Bedard PL, Singhai SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012; 18:1341-1351.
17. Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, et al. Breast carcinoma with brain metastases:clinical analysis and immunoprofile on tissue microarrays. Ann Oncol 2011; 22:2597-2603.
18. Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS. Emerging Roles of Angiopoietin-like 4 in Human Cancer. Mol Cancer Res 2012; 10:677-688.
19. Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair with cancers. J Oncol 2012; 2012:351089.
20. Chu JE, Allan AL. The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil. Int J Breast Cancer 2012; 2012:209748.
21. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133:66-77.
22. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-3327.
23. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638-2645.
24. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012; 31:1757-1770.
25. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012; 90:803-815.
26. Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 16; 7:9.
27. Shi H, Bevier M, Johansson R, Grzybowska E, Chen B, Eyfjörd JE, et al. Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome. Breast Cancer Res Treat 2011; 130:905-916.
28. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
29. Glinsky GV, Olga Berezovska, Anna B Glinskii. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115:1503-1521.
30. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006; 12:405-410.
31. Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, et al. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013; 19:1063-1073.
32. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6:17-32.
33. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 2009; 28:742-751.
34. Mizukami Y, Nonomura A, Takizawa T, Noguchi M, Michigishi T, Nakamura S, Ishizaki T. N-myc protein expression in human breast carcinoma: prognostic implications. Anticancer Res 1995; 15:2899-2905.
35. Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, Abad BM, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res 2008; 68:6092-6099.
36. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelialmesenchymal transition, and cancer stem cell properties. Oncogene 2012; 31:552-562.